Time to Initiation of Adjuvant Chemotherapy in Pancreas Cancer: A Multi-Institutional Experience

Abstract

Despite randomized trials addressing adjuvant therapy (AT) for pancreas cancer, the ideal time to initiate therapy remains undefined. Retrospective analyses of the ESPAC-3 trial demonstrated that time to initiation of AT did not impact overall survival (OS). Given the absence of confirmatory data outside of a clinical trial, we sought to determine if AT… (More)
DOI: 10.1245/s10434-017-5918-z

5 Figures and Tables

Topics

  • Presentations referencing similar topics